caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a inflammatory, nutrient, energy source, immunomodulator, membrane stabilizer, energy storage. | Nc1nc(=O)c2c([nH]1)NCC([C@H](O)[C@H](O)CO)=N2 | [
"inflammatory",
"nutrient",
"Energy source",
"immunomodulator",
"Membrane stabilizer",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts tangier disease, diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure that impacts tangier disease, aging, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, inflammatory, fat storage, nutrient, membrane stabilizer that impacts obesity. It impacts cancer, cardiovascular disease, and thyroxine treatment. The molecule is a energy storage that impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCCCCC(C)C | [
"Energy source",
"Obesity",
"inflammatory",
"Fat storage",
"nutrient",
"Membrane stabilizer",
"Cancer",
"Cardiovascular disease",
"Thyroxine treatment",
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and a nutrient that impacts metabolic syndrome, atherosclerosis, cancer, and cardiovascular disease. The molecule is a energy source and energy storage, and it impacts obesity. The molecule is a membrane stabilizer and a inflammatory, it impacts pancreatitis, and is thyroxine treatment. | CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)CC | [
"Metabolic syndrome",
"Atherosclerosis",
"Fat storage",
"nutrient",
"Cancer",
"Cardiovascular disease",
"Energy source",
"Energy storage",
"Obesity",
"Thyroxine treatment",
"Pancreatitis",
"Membrane stabilizer",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts aging, diabetic heart disease, and tangier disease. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fluorescent and belongs to the fluorescent dye class of molecules. | CCOC(=O)Cc1cc[n+](CCCS(=O)(=O)O)cc1 | [
"fluorescent",
"fluorescent dye"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It influences both stomach cancer and colorectal cancer, as well as affecting diabetes mellitus and cardiovascular disease. It impacts parkinson's disease, seizure, alzheimer's disease, and breast cancer. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\C=C\C(=O)CCCCC | [
"Diabetes mellitus",
"Stomach cancer",
"Colorectal cancer",
"Cardiovascular disease",
"Parkinson's disease",
"Seizure",
"Alzheimer's Disease",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a emulsifier, impacting both tangier disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, a food additive, and a stabilizing mitochondrial structure, it impacts diabetic heart disease and is smooth. The molecule is a ... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Emulsifier",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Smooth",
"food additive",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the tgr5 agonist class and affects type ii diabetes treatment. | Clc1cc(C(Br)Br)c(Cl)cc1C(Br)Br | [
"tgr5 agonist",
"type ii diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | C=CC(=O)N(C)CCCC(CC)n1c(NC(=O)c2ccc(-c3ccc(NC)nc3)s2)nc2ccccc21 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nonaqueous electrolyte and belongs to the electrolyte class of molecules. | Cc1ccc(S(=O)(=O)Oc2ccc(C(C)(C)C)cc2C(C)(C)C)cc1 | [
"electrolyte",
"nonaqueous electrolyte"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, a sedative, a anti streptococcic, and lemon. The molecule is a nematicide, which belongs to the acaricide class of molecules, and is fat, aldehydic, and fungicide. The molecule is a allergen and irritant, belonging to the anti septic class of molecules, and is citrus. The molecule is a energ... | CC(=O)C1CC(=O)C2(C)C3=C(C(=O)CC12C)C1(C)CCC(=O)C(C)(C)C1CC3O | [
"lemon",
"nutrient",
"sedative",
"anti streptococcic",
"fat",
"nematicide",
"aldehydic",
"acaricide",
"fungicide",
"allergen",
"anti septic",
"citrus",
"irritant",
"anti staphylococcic",
"Energy source",
"cherry",
"herbal",
"insectifuge",
"dry",
"Energy storage",
"mutagenic",... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammation treatment and a anti inflammatory, belonging to the leukotriene antagonist class of molecules. | CCOC(=O)C(C)Oc1c(COc2ccc3oc(-c4nc(C(C)(C)C)cs4)cc3c2)cccc1OC | [
"leukotriene antagonist",
"inflammation treatment",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1cc2ccc(=O)oc2cc1OC(C)=O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral. | COC(OC)C(CC#N)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(Cc1ccccc1C)NC(=O)C(CCC(=O)OC(C)(C)C)NC(=O)C(CC(=O)OC(C)(C)C)NC(=O)CCC(=O)OC(C)(C)C)C(C)(C)C | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts breast cancer, parkinson's disease, and diabetes mellitus. It impacts cardiovascular disease, alzheimer's disease, seizure, and colorectal cancer. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C/C/C=C\C[C@H](O)/C=C\C=C/CCCCC)COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O | [
"Breast cancer",
"Parkinson's disease",
"Stomach cancer",
"Diabetes mellitus",
"Cardiovascular disease",
"Alzheimer's Disease",
"Seizure",
"Colorectal cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts tangier disease, aging, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Tangier disease",
"Aging",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, surfactant, emulsifier, energy storage, and green. The molecule is a nutrient, membrane stabilizer, energy source, jam, berry, and fruity. | CCC/C=C/CCOC(C)=O | [
"Flavoring agent",
"green",
"surfactant",
"Emulsifier",
"Energy storage",
"jam",
"berry",
"nutrient",
"fruity",
"Membrane stabilizer",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts barth syndrome, tangier disease, diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic light-emitting diode. | C=Cc1sc2ccccc2c1C=C(C)c1cc(-n2c3ccccc3c3cc(-c4cccc5c6ccccc6n(-c6ccccc6)c45)ccc32)cc2c1sc1ccccc12 | [
"organic light-emitting diode"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, diabetic heart disease, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a sodium channel inhibitor. | COc1cc(-c2cc(C)cc(F)c2)c(C)cc1N(c1ccon1)S(=O)(=O)c1ccc2cnccc2c1 | [
"sodium channel inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor that impacts cancer treatment. | COc1ccc2nccc(Oc3ccc4[nH]c(C)cc4c3F)c2c1 | [
"kinase inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, alzheimer's disease, and diabetes mellitus type 2. | CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\[C@@H](O)CCCC)COP(=O)(O)OCCN | [
"nutrient",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source and a inflammatory that impacts pancreatitis, cardiovascular disease, thyroxine treatment, and obesity. The molecule is a nutrient and membrane stabilizer, and it impacts atherosclerosis. The molecule is a energy storage and a fat storage, impacting both cancer and metabolic syndrome. | CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Pancreatitis",
"Cardiovascular disease",
"Energy source",
"inflammatory",
"Thyroxine treatment",
"Obesity",
"nutrient",
"Atherosclerosis",
"Membrane stabilizer",
"Energy storage",
"Cancer",
"Metabolic syndrome",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cardiovascular disease, pancreatitis, and thyroxine treatment. The molecule is a fat storage and a nutrient, impacting both atherosclerosis and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"Metabolic syndrome",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti cancer. | CCOC(SC(c1ccccc1)(c1ccccc1)c1ccccc1)C(NC(=O)OC(C)(C)C)C(N)=O | [
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both pancreatitis and atherosclerosis. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCCCC | [
"Pancreatitis",
"Fat storage",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is abc transporter modulator. | C=CC1=C(S)CCCC1 | [
"abc transporter modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, aging, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, energy source, membrane stabilizer, surfactant, emulsifier, nutrient. | CC(C)(O)/C=C/CC(C)(O)C1C(=O)CC2(COC3OC(COC4OCC(O)C(O)C4O)C(O)C(O)C3O)C1CCC1C3(C)CCC(OC4OCC(O)C(O)C4O)C(C)(C)C3CCC12C | [
"Energy storage",
"Energy source",
"Membrane stabilizer",
"surfactant",
"Emulsifier",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, nutrient, membrane stabilizer that impacts metabolic syndrome, cancer, and cardiovascular disease. The molecule is a energy source that impacts both obesity and thyroxine treatment. The molecule is a energy storage and a inflammatory, impacting both pancreatitis and atherosclerosis. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Cancer",
"Fat storage",
"Cardiovascular disease",
"nutrient",
"Membrane stabilizer",
"Obesity",
"Thyroxine treatment",
"Energy source",
"Energy storage",
"inflammatory",
"Pancreatitis",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a autoimmune treatment, a jak inhibitor, and cancer treatment. | O=c1[nH]cc(Br)c2c1c(Nc1cccc(S)c1)nn2C1CCCC1 | [
"cancer treatment",
"autoimmune treatment",
"jak inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition, it emits very toxic fumes of hydrogen chloride, nitrogen oxides and hydrogen cyanide. | CCNc1nc(Cl)nc(NC(C)(C)C#N)n1 | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a tachykinin receptor antagonist. | CNCC1CCC(OCCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1c1ccc(F)cc1 | [
"tachykinin receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a integrin antagonist and belongs to the cancer treatment class of molecules, with the characteristic of being osteoporosis treatment. | O=C(NCc1cccnc1)Nc1cccc(-c2ccc(CC(NS(=O)(=O)c3ccc(Cl)cc3)C(=O)O)cc2)c1 | [
"integrin antagonist",
"osteoporosis treatment",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, energy source. The molecule is a membrane stabilizer and a cholesterol translocation that impacts tangier disease, aging, and barth syndrome. The molecule is a food additive, a emulsifier, a apoptosis, and smo... | CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Nutritional supplement",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Energy source",
"Tangier disease",
"Aging",
"Membrane stabilizer",
"Barth syndrome",
"Cholesterol translocation",
"Smooth",
"food additive",
"Emulsifier",
"Apoptosis",
"Diabetic heart diseas... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, inflammatory, energy storage that has an effect on cancer and impacts atherosclerosis. The molecule is a energy source and thyroxine treatment, and it impacts pancreatitis. The molecule is a fat storage that impacts obesity, cardiovascular disease, and metabolic syndrome... | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"nutrient",
"Cancer",
"Membrane stabilizer",
"inflammatory",
"Energy storage",
"Atherosclerosis",
"Energy source",
"Pancreatitis",
"Thyroxine treatment",
"Obesity",
"Cardiovascular disease",
"Fat storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Pungent odor. When heated to decomposition ... it emits highly toxic fumes of hydrogen bromide. | CCOC(=O)CBr | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C=C\[C@H](O)C/C=C\CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fundamental metabolite and hepatotonic, belonging to both the diuretic and cholesterolytic classes of molecules. | O=C(O)[C@H](O)CO | [
"fundamental metabolite",
"diuretic",
"cholesterolytic",
"hepatotonic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a chemokine receptor modulator and hiv treatment, and it impacts cancer treatment. | O=C(NNc1ccc(F)cc1F)c1ccc(CNCc2ccccc2)cc1 | [
"chemokine receptor modulator",
"hiv treatment",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The organic electroluminescent class molecule influences low voltage and is electroluminescent. | c1ccc(C2(c3ccc(N(c4ccc(-c5cccc6c5sc5ccccc56)cc4)c4cccc5c4-c4ccccc4C54c5ccccc5-c5ccccc54)cc3)c3ccccc3-c3ccccc32)cc1 | [
"low voltage",
"organic electroluminescent",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, tangier disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti septic that is pesticide, anti spasmodic, and anti inflammatory; additionally, it is anti anaphylactic. | CC/C=C/CCOC(=O)c1ccccc1 | [
"anti septic",
"pesticide",
"anti spasmodic",
"anti inflammatory",
"anti anaphylactic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and tangier disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and aging. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, nutrient that impacts obesity, atherosclerosis, and cardiovascular disease. The molecule is a membrane stabilizer that affects cancer by impacting pancreatitis. The molecule is a energy source, a inflammatory, and a thyroxine treatment, and it impacts metabolic syndrome. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)C | [
"Energy storage",
"Fat storage",
"Obesity",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Membrane stabilizer",
"Pancreatitis",
"Cancer",
"Metabolic syndrome",
"Energy source",
"inflammatory",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a food additive and a energy source, impacting both barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase, a nutritional supplement, and a energy storage, it impacts diabetic heart disease and is smooth. The molecule is a cholesterol translocation, apoptosis, surfactant, p... | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"food additive",
"Energy source",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Nutritional supplement",
"Energy storage",
"Smooth",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"surfactant",
"Proton trap for oxidative phosphorylation",
"Non... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the liquid crystal class of molecules. | CCCCCCCc1ccc(-c2ccc(OC)c(F)c2)nc1 | [
"liquid crystal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1cc(CC(O)CO)ccc1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome. The molecule is a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts tangier disease and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\[C@@H](O)CCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both pancreatitis and atherosclerosis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Pancreatitis",
"Atherosclerosis",
"nutrient",
"Fat storage",
"Thyroxine treatment",
"Metabolic syndrome",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging and tangier disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the cancer treatment class of molecules. | CC(c1ccc2nc[nH]c2c1)c1cnc(N)nc1Nc1cc(C2CC2(F)F)[nH]n1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a diabetes treatment member of the obesity treatment class. | CC(=O)c1cccc(-c2ccc(C(=O)Nc3ccc(N4CCC(N(C)C)C4)cc3)cc2)c1 | [
"diabetes treatment",
"obesity treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a electroluminescent member of the organic electroluminescent class. | C1=CC(N(c2ccccc2)c2ccc(-c3ccc4ccccc4c3)cc2)=C(c2ccc(-c3ccccc3N(c3ccccc3)c3cccc4ccccc34)cc2)CC1 | [
"electroluminescent",
"organic electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a liquid crystal compound and a liquid crystalline. | CCCC1CCC(CCc2ccc(CC=CF)cc2)CC1 | [
"liquid crystal compound",
"liquid crystalline"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a positive allosteric modulator. | Cn1c(=O)n(CC(C)(C)C)c2ccc(-c3ccc(N4CCN(C(=O)c5cscn5)CC4)cc3)nc21 | [
"positive allosteric modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, a nutrient, berry, phenolic, and medical. | Oc1cc(O)c2c(c1)O[C@@]1(c3ccc(O)c(O)c3)Oc3cc(O)c4c(c3[C@@H]2[C@H]1O)O[C@H](c1ccc(O)c(O)c1)[C@H](O)[C@H]4c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2 | [
"berry",
"phenolic",
"medical",
"Flavoring agent",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protease inhibitor and a renin inhibitor, belonging to the hypertension treatment class of molecules. | CN(CC(C=O)NC(=O)OC(C)(C)C)C(=O)O | [
"protease inhibitor",
"renin inhibitor",
"hypertension treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a energy source, and a surfactant, and it impacts aging. The molecule is a stabilizing mitochondrial structure, energy storage, nutritional supplement that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation, a membrane stabilizer... | CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Emulsifier",
"Aging",
"Energy source",
"surfactant",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Energy storage",
"Nutritional supplement",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Membrane stabilizer",
"Cholesterol translocation",
"Smooth",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a rho kinase inhibitor. | N#Cc1cccc(C(N)CCO)c1 | [
"rho kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, inflammatory, energy storage that impacts cancer, metabolic syndrome, and cardiovascular disease. The molecule is a member of the thyroxine treatment class and affects both obesity and pancreatitis. The molecule is a nutrient, a membrane stabilizer, and a energy source, and it impacts ath... | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Fat storage",
"inflammatory",
"Cancer",
"Metabolic syndrome",
"Energy storage",
"Cardiovascular disease",
"Obesity",
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis",
"nutrient",
"Membrane stabilizer",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor. | CN(C)C=CC(=O)c1ccc2[nH]c(=O)c3[nH]ccc3c2c1 | [
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C(=O)OCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti proliferative and a cancer treatment, belonging to the anti neoplastic class of molecules. | Cc1cccc(C=CS(=O)(=O)NC(=O)c2ccc(Cl)cc2Cl)n1 | [
"anti proliferative",
"cancer treatment",
"anti neoplastic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a apoptosis and a cholesterol translocation that impacts diabetic heart disease, tangier disease, and aging. | CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a factor xa inhibitor. | O=C(Nc1ccc(Cl)cc1)NC1(C(=O)O)CCNCC1 | [
"factor xa inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, a emulsifier, a nutrient, and ethereal. The molecule is a membrane stabilizer, a surfactant, a energy source, and sweet. | CCCCOC(=O)CCC(C)=O | [
"ethereal",
"Energy storage",
"Emulsifier",
"nutrient",
"Membrane stabilizer",
"surfactant",
"Energy source",
"sweet"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Cholesterol translocation",
"Diabetic heart disease",
"Aging",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the anti biotic and anti bacterial classes of molecules. | CC(OC(=O)OCc1ccc([N+](=O)[O-])cc1)C1C(=O)N2C(C(=O)OCc3ccc([N+](=O)[O-])cc3)=C(Sc3nccc(N)n3)CC12 | [
"anti biotic",
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the photoresist class of molecules. | CC(C)(C)CC(C)(C(=O)OCC(=O)OC1CCCCC1)C(C)(C)C | [
"photoresist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a beta-lactamase inhibitor and belongs to the anti bacterial class of molecules, with the characteristic of being anti bacterial agent. | NC1CC1C(=O)NNC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O | [
"beta-lactamase inhibitor",
"anti bacterial",
"anti bacterial agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ra inhibitor, raf kinase inhibitor, raf inhibitor and belongs to the cancer treatment class of molecules. | OCCN1CCC(c2cc(-c3ccncc3)c(-c3ccc4c(c3)CCC4=NO)o2)CC1 | [
"cancer treatment",
"ra inhibitor",
"raf kinase inhibitor",
"raf inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, energy source, energy storage, emulsifier. The molecule is a apoptosis, stabilizing cytochrome oxidase, surfactant that impacts diabetic heart disease and aging. The molecule is a food additive, a membrane stabilizer, a proton trap for oxidative phosphorylation, an... | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Stabilizing mitochondrial structure",
"Energy source",
"Energy storage",
"Emulsifier",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Stabilizing cytochrome oxidase",
"surfactant",
"food additive",
"Membrane stabilizer",
"Smooth",
"Proton trap for oxidative phosphorylation",
"Tangier di... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, a nutrient, and a membrane stabilizer. The molecule is a energy storage, surfactant, waste product, emulsifier. | CC(=O)OCC1OC(OC2C(OC(C)=O)C(C)OC(OC(=O)C34CCC(C)(C)CC3C3=CCC5C6(C)CCC(OC7OC(C(=O)O)C(O)C(OC8OCC(O)C(O)C8O)C7OC7OC(CO)C(O)C(O)C7O)C(C)(C=O)C6CCC5(C)C3(C)CC4O)C2OC2OC(C)C(OC3OCC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1O | [
"Energy source",
"nutrient",
"Membrane stabilizer",
"Energy storage",
"surfactant",
"Waste product",
"Emulsifier"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cox2 inhibitor and a cyclooxygenase2 inhibitor, belonging to the anti inflammatory class of molecules. | CCOC(=O)C1=Cc2cc(C)cc(CNc3ccccc3)c2OC1C(F)(F)F | [
"cox2 inhibitor",
"anti inflammatory",
"cyclooxygenase2 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a depression treatment and a nmda antagonist. | CC(C)(C)OC(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(Cc1ccccn1)c1ccccc1 | [
"depression treatment",
"nmda antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | CCCC(=O)N1CCCC1c1ncc(-c2ccc3c(c2)COc2cc4c(ccc5[nH]c(CN(C(=O)CNC)C(C)CC)nc54)cc2-3)[nH]1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, energy storage, nutrient, membrane stabilizer, surfactant, emulsifier. | COc1cc(OC/C=C(\C)CCC=C(C)C)c2ccc(=O)oc2c1 | [
"Energy source",
"Energy storage",
"nutrient",
"Membrane stabilizer",
"surfactant",
"Emulsifier"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.